Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _______________________________ FORM 10-Q _______________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ________ Commission File Number 001-37687 ______________ ...

Clinical Development - Achieved in vivo preclinical proof of concept for hematopoietic stem and progenitor cell editing, demonstrating a 29% editing level in HSPCs after a single dose[3] - Induced fetal hemoglobin (HbF) expression in human red blood cells, with an average of 20% HbF expressing cells present one month post-treatment[3] - Reni-cel (renizgamglogene autogedtemcel) is on track to present clinical data at the ASH Annual Meeting on December 7-10, 2024, following the completion of enrollment for adolescent and adult cohorts in the RUBY trial[4] - Completed enrollment of the adult cohort in the EdiTHAL trial for transfusion-dependent beta thalassemia, with additional clinical data expected by year-end 2024[5] Financial Performance - Sold future license fees under the Cas9 license agreement to DRI Healthcare Trust for an upfront cash payment of $57 million, enhancing non-dilutive capital for pipeline development[6] - Ended Q3 2024 with approximately $265 million in cash, cash equivalents, and marketable securities, increasing to approximately $320 million post-receipt of DRI payment[6] Strategic Partnerships - Engaged Moelis & Company LLC to lead the global process for partnering or out-licensing reni-cel, aiming to reduce spending in 2025[6] - Focused on optimal capital use while advancing the in vivo pipeline and evaluating opportunities for reni-cel commercialization[2] Technology and Innovation - The proprietary targeted lipid nanoparticle (tLNP) formulation is key for extrahepatic tissue delivery, positioning the company for leadership in in vivo programmable gene editing[2] - The company aims to deliver transformative genomic medicines for serious diseases, leveraging CRISPR/Cas12a and Cas9 genome editing systems[8]

Achieved in vivo preclinical proof of concept of HBG1/2 editing in hematopoietic stem and progenitor cells (HSPCs) using Editas Medicine’s proprietary targeted LNP in a key step to developing a novel in vivo treatment for sickle cell disease and beta thalassemia On track to share additional clinical and patient reported outcomes data from 28 patients in the RUBY trial for sickle cell disease at the American Society of Hematology (ASH) Annual Meeting and Exposition in December Company to provide an update on ...

Editas Medicine (EDIT) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, t ...

Shares of Editas Medicine (EDIT) plunged 12.5% on Tuesday after announcing that it is seeking a global partner to advance its lead gene editing therapy, reni-cel, which is being developed for certain non-malignant hematologic diseases, or potentially out-license rights to the treatment entirely, amid a significant cash crunch. Editas firmly believes that this decision is in the best interests of its patients and shareholders, as a potential partnership agreement would allow for further development and ultim ...

Editas Medicine, Inc. (EDIT) announced that it has entered into a collaboration and nonexclusive license agreement with Canada-based privately held company Genevant Sciences to develop in vivo gene editing medicines. Shares of Editas were up 2.4% in after-hours trading on Oct. 21, following the announcement of the news. The partnership aims to leverage Editas' CRISPR Cas12a genome editing systems with Genevant's proprietary lipid nanoparticle (LNP) technology to develop novel mRNA-LNP gene editing therapies ...

Stephanie and Tristan LIVING WITH SICKLE CELL DISEASE Strategic Update October 2024 Forward Looking Statements This presentation contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words ''anticipate,'' ''believe,'' ''continue,'' ''could,'' ''estimate,'' ''expect,'' ''intend,'' ''may,'' ''plan,'' ''potential,'' ''predict,'' ''project,'' ''target,'' ''should,'' ''would,'' and similar expressions are intended to identify forward-l ...

Editas Medicine, Inc. (NASDAQ:EDIT) Strategic Update Conference Call October 22, 2024 8:00 AM ET Company Participants Cristi Barnett - Corporate Communications and IR Gilmore O'Neill - Chief Executive Officer Linda Burkly - Chief Scientific Officer Erick Lucera - Chief Financial Officer Baisong Mei - Chief Medical Officer Caren Deardorf - Chief Commercial and Strategy Officer Conference Call Participants Samantha Semenkow - Citi Gena Wang - Barclays Jack Allen - Baird Yanan Zhu - Wells Fargo Soumit Roy - Jo ...

Company Overview - Editas Medicine, Inc. held a Strategic Update Conference Call on October 22, 2024, at 8:00 AM ET, featuring key executives including the CEO, CFO, and Chief Scientific Officer [1]. Participants - The conference call included participation from various financial institutions such as Citi, Barclays, Baird, Wells Fargo, and JPMorgan Chase, among others [1]. Future Expectations - The company made forward-looking statements regarding its future expectations, plans, and prospects, which are protected under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995 [2].

CAMBRIDGE, Mass. and VANCOUVER, British Columbia and BASEL, Switzerland, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, and Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio, today announced that they have entered into a collaboration and nonexclusive license agreement to combine Editas Medicine’s CRISPR Cas12a genome editing systems with Genevant’s propr ...